Noninvasive Stool DNA Testing May Outperform Colonoscopy Long-Term in Real-World CRC Screening

Why It Matters

Because adherence determines screening effectiveness, mt‑sDNA could deliver greater public‑health impact while easing colonoscopy capacity constraints.

Key Takeaways

• mt-sDNA adherence ~72%, colonoscopy ~38%.
• Detects 13% more precancerous lesions than colonoscopy.
• Achieves 33% CRC mortality reduction versus 20% for colonoscopy.
• Generates 62% more life‑years gained over ten years.
• Expands screening capacity amid limited colonoscopy resources.

Pulse Analysis

Colorectal cancer remains the second leading cause of cancer death in the United States, and screening adherence has long been a bottleneck. Colonoscopy, while highly sensitive, requires bowel preparation, sedation, and specialist time, leading to modest uptake—often below 40% in average‑risk populations. In contrast, multitarget stool DNA testing can be performed at home without preparation, which has driven a rapid rise in its use from less than 1% of screenings in 2015 to nearly 9% by 2018. This shift reflects a broader patient preference for convenient, noninvasive options, a trend that directly influences public‑health outcomes.

The modeling analysis incorporated real‑world adherence data and test performance metrics to compare three mt‑sDNA rounds against a single colonoscopy over a decade. Higher adherence amplified the modest sensitivity advantage of stool DNA, resulting in more early detections, a 33% mortality reduction, and substantially more life‑years saved. Sensitivity analyses confirmed that even with varied adherence rates, mt‑sDNA consistently outperformed colonoscopy, underscoring the critical role of patient behavior in screening effectiveness. While colonoscopy retains superiority under perfect adherence, achieving such rates in practice remains unlikely.

For policymakers and health systems, these findings suggest that expanding coverage and reimbursement for mt‑sDNA could boost overall screening rates, alleviate endoscopy backlogs, and improve equity by reaching underserved populations. Future research should integrate cost‑effectiveness and lifetime horizon analyses to fully quantify economic benefits. As the CRC screening landscape evolves, leveraging high‑adherence, at‑home tests may become a cornerstone of population‑level cancer control strategies.